AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology ...

Globus Medical Q4 sales hit $826.4M, up 25.7%, driven by spine growth and successful NuVasive, Nevro integrations; analysts ...

Globus Medical’s second quarter sales for 2025 reached $745.3 million, a year-over-year increase of 18.4%, led largely by its U.S. spine business. The company, which is a top player in the ...

Medical device company Globus Medical (NYSE:GMED) reported in Q4 CY2025, with sales up 25.7% year on year to $826.4 million. The company’s full-year revenue guidance of $3.2 billion at the midpoint ...

Globus is a remarkable non-profit service from the University of Chicago: it's a comprehensive platform for research data management, serving the academic, scientific, businesses and commercial ...

Globus Medical is rated Hold, as growth is increasingly reliant on M&A and organic momentum remains muted. GMED's FY26 guidance implies 9% revenue growth, a sharp deceleration from FY25's 16.5%, with ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsBrian Kearns - Senior Vice President of ...

Globus Medical Inc. (NYSE:GMED) is one of the best medical technology stocks to invest in. On January 30, Needham upgraded ...

Globus Medical, Inc. GMED reported adjusted earnings per share (EPS) of 57 cents in the third quarter of 2023, beating the Zacks Consensus Estimate by 5.6%. The metric increased 14% year over year.

The Globus family of brands has launched a new portal and education platform for travel advisors, along with a B2B ad campaign that highlights the importance of advisors to Globus' business. The ...

AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth ...